Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Newly Public AGA Medical Reports 15% Sales Growth In Third Quarter

This article was originally published in The Gray Sheet

Executive Summary

AGA Medical, maker of Amplatzer structural heart defect repair devices and vascular disease treatments, reported third-quarter sales growth of 14.9% to $50.2 million on Nov. 3 - two weeks after going public in a $200 million initial public offering

You may also be interested in...



Private Equity Firm Signals Interest In Devices With K2M Investment

Welsh, Carson, Anderson & Stowe, a long-time investor in health care services companies, signaled its intent to invest more deeply in the device sector with the acquisition of a majority position in spinal company K2M

Private Equity Firm Signals Interest In Devices With K2M Investment

Welsh, Carson, Anderson & Stowe, a long-time investor in health care services companies, signaled its intent to invest more deeply in the device sector with the acquisition of a majority position in spinal company K2M

Medtronic v. AGA Medical

Heart defect repair device maker AGA Medical will pay Medtronic $35 million over four years to settle charges that AGA's Amplatzer occluder and vascular plug devices infringed Medtronic's Jervis patents, the firms announce March 29. Medtronic brought the suit in 2007. The last of the three patents, which relate to shape memory alloy stents, is scheduled to expire in 2018. The settlement amount is lower than an initial jury award last August of $57.8 million in damages to Medtronic, and the non-exclusive license granted to AGA does not require royalty payments on future sales (1"The Gray Sheet" Nov. 9, 2009)

Related Content

Topics

UsernamePublicRestriction

Register

MT028145

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel